Cyril H Benes Selected Research

ONC212

12/2019	Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
10/2017	Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.
10/2017	Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cyril H Benes Research Topics

Disease

75	Neoplasms (Cancer) 04/2024 - 07/2011
16	Lung Neoplasms (Lung Cancer) 04/2024 - 09/2011
8	Breast Neoplasms (Breast Cancer) 04/2024 - 12/2013
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 03/2013
6	Neuroblastoma 01/2022 - 01/2015
6	Ewing Sarcoma (Sarcoma, Ewing) 10/2021 - 03/2012
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 01/2015
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 01/2018
4	Hypersensitivity (Allergy) 01/2019 - 01/2015
3	Cholangiocarcinoma 01/2022 - 01/2016
3	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 01/2017
3	Melanoma (Melanoma, Malignant) 10/2017 - 01/2015
2	Multiple Myeloma 04/2024 - 01/2018
2	Liver Neoplasms (Liver Cancer) 01/2023 - 10/2017
2	Carcinogenesis 10/2021 - 01/2018
2	Neoplasm Metastasis (Metastasis) 10/2021 - 02/2013
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021 - 01/2018
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019 - 01/2018
2	Adenocarcinoma 01/2019 - 07/2014
2	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 01/2014
2	Disease Progression 10/2016 - 11/2014
2	Oncogene Addiction 03/2012 - 09/2011
1	Triple Negative Breast Neoplasms 11/2022
1	Colonic Neoplasms (Colon Cancer) 01/2022
1	Squamous Cell Carcinoma of Head and Neck 01/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 12/2021
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2019

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2013
12	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2012
9	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 01/2013
9	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019 - 03/2012
6	Phosphotransferases (Kinase)IBA 01/2022 - 09/2011
6	venetoclaxIBA 01/2021 - 02/2016
6	RNA (Ribonucleic Acid)IBA 01/2019 - 09/2011
5	Drug CombinationsIBA 01/2023 - 12/2014
5	ErbB Receptors (EGF Receptor)IBA 12/2021 - 10/2013
5	DNA (Deoxyribonucleic Acid)IBA 04/2019 - 03/2013
4	ChromatinIBA 04/2019 - 05/2014
4	olaparibIBA 01/2019 - 10/2013
4	TIC10 compoundIBA 01/2018 - 01/2017
3	Tyrosine Kinase InhibitorsIBA 04/2024 - 12/2014
3	Mitogen-Activated Protein KinasesIBA 01/2022 - 01/2017
3	Adenosine Triphosphate (ATP)IBA 01/2021 - 01/2018
3	Mechanistic Target of Rapamycin Complex 1IBA 11/2020 - 01/2014
3	lorlatinibIBA 01/2020 - 01/2018
3	ONC212IBA 12/2019 - 10/2017
3	navitoclaxIBA 01/2019 - 03/2015
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2018 - 03/2012
3	Small Interfering RNA (siRNA)IBA 01/2018 - 01/2013
3	Anaplastic Lymphoma KinaseIBA 01/2018 - 12/2014
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 10/2017
2	SHP099IBA 01/2022 - 01/2022
2	EWS-FLI fusion proteinIBA 10/2021 - 01/2019
2	GSK-J4IBA 10/2021 - 01/2018
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020 - 05/2014
2	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 04/2019 - 01/2015
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2019 - 12/2014
2	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2019 - 07/2011
2	Transcription Factors (Transcription Factor)IBA 12/2018 - 01/2018
2	Lysine (L-Lysine)FDA Link 01/2018 - 03/2015
2	Complement System Proteins (Complement)IBA 12/2017 - 10/2015
2	CrizotinibIBA 10/2017 - 10/2016
2	Cisplatin (Platino)FDA LinkGeneric 10/2013 - 03/2013
2	Tyrosine (L-Tyrosine)FDA Link 02/2013 - 07/2011
1	Alkylating AgentsIBA 01/2023
1	UbiquitinIBA 11/2022
1	EnzymesIBA 11/2022
1	TAK-243IBA 11/2022
1	tyrosine receptor (receptor, tyrosine)IBA 01/2022
1	EpiregulinIBA 01/2022
1	Focal Adhesion Protein-Tyrosine KinasesIBA 12/2021
1	RNA Polymerase II (RNA Polymerase B)IBA 10/2021
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 10/2021
1	AZD3965IBA 01/2021
1	NVP-CGM097IBA 01/2021
1	Topotecan (Hycamtin)FDA LinkGeneric 01/2021
1	Monocarboxylic Acid TransportersIBA 01/2021
1	S63845IBA 01/2021
1	AlginatesIBA 01/2021
1	Phenformin (Fenformin)IBA 01/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021
1	Vacuolar Proton-Translocating ATPases (V-Type ATPase)IBA 11/2020
1	verucopeptinIBA 11/2020
1	Adenosine Triphosphatases (ATPase)IBA 11/2020
1	Nucleic AcidsIBA 01/2020
1	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2020
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 12/2019
1	MTOR InhibitorsIBA 01/2019
1	infigratinibIBA 01/2019
1	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 01/2019
1	futibatinibIBA 01/2019
1	CH5183284IBA 01/2019
1	Proto-Oncogene Proteins c-bcl-2 (Proto Oncogene Proteins c bcl 2)IBA 12/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 10/2018
1	MicroRNAs (MicroRNA)IBA 01/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018

Therapy/Procedure

37	Therapeutics 04/2024 - 03/2012
8	Drug Therapy (Chemotherapy) 12/2021 - 09/2011
1	Aftercare (After-Treatment) 01/2020